Robert A. Brodsky, MD.PNH SCIENTIFIC ADVISORY BOARD
Director, Division of Hematology, Professor of Medicine and Oncology, Johns Hopkins Hospital, USA
Professor Brodsky did his residencies in Vanderbilt University School of Medicine, in Internal Medicine, Nashville, TN. He pursued a fellowship in Hematology at the National Institutes of Health, Bethesda, MD (1994), then in Oncology at Johns Hopkins University School of Medicine, Baltimore, MD (1997). He received his medical degree from Hahnemann University, PA and has been in practice for 26 years. Dr. Brodsky is board certified in Internal Medicine and Hematology (2006).
Dr. Brodsky’s major clinical research involves the study of aplastic anemia, PNH and other bone marrow failure disorders. His research shows that immunoablative doses of cyclophosphamide, without bone marrow transplantation, can lead to durable complete remissions in severe aplastic anemia. The reason high-dose cyclophosphamide is able to ablate the effector cells without destroying hematopoietic stem cells is that the earliest stem cells (but not lymphocytes) contain high levels of aldehyde dehydrogenase conferring resistance to the cytoxic properties of cyclophosphamide. Dr. Brodsky and his colleagues in Oncology are applying this approach to prevent alloimmunity in the setting of bone marrow transplantation which has allowed for the safe and effective use of HLA-haploidentical donor bone marrow transplantation for nonmalignant diseases such as aplastic anemia and sickle cell disease. Dr. Brodsky’s major laboratory interests relate to the study of complement-mediated diseases such as PNH and atypical hemolytic uremic syndrome (aHUS). His group has developed a novel diagnostic assay (FLAER) for PNH based on the pore forming toxin (aeromonas hydrophila). Recently, his group has developed a modified HAM test to diagnose aHUS.